We are live on ! Find out more
ATHE

Alterity Therapeutics

12 hedge funds and large institutions have $834K invested in Alterity Therapeutics in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 1

100% more capital invested

Capital invested by funds: $416K → $834K (+$418K)

0% more ownership

Funds ownership: 0%0% (+0%)

0% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 2

8% less funds holding

Funds holding: 1312 (-1)

Holders
12
Holders Change
-1
Holders Change %
-7.69%
% of All Funds
0.16%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
4
Reduced
1
Closed
2
Calls
Puts
Net Calls
Net Calls Change

ATHE Hedge Fund Activity: Q1 2025 in Review

12 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q1 2025, worth a combined $834K — up 100% from $416K a quarter earlier.

Fund positioning in ATHE was balanced in Q1 2025: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 1 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $379K. The largest seller was Morgan Stanley, cutting an estimated $2.68K.

  • 12 institutional investors held Alterity Therapeutics (ATHE) as of Q1 2025, down from 13 in Q4 2024.
  • Funds reported $834K of Alterity Therapeutics stock for Q1 2025, up 100% quarter-over-quarter.
  • 2 funds opened new Alterity Therapeutics positions in Q1 2025 and 2 closed out, a net change of 0 holders.
  • The largest Alterity Therapeutics buyer in Q1 2025 was Point72 Asset Management, an estimated $379K added.
  • The largest Alterity Therapeutics seller in Q1 2025 was Morgan Stanley, an estimated $2.68K sold.

Based on aggregated 13F filings for Q1 2025.